Switch theme
Sign up to access all valuation multiples
R&G PharmaStudies Co Ltd is a clinical trial outsourcing service provider. It offers full-chain clinical research outsourcing services, serving global pharmaceutical and medical device companies and scientific research institutions.
2008
n/a
LTM Revenue $104M
LTM EBITDA $24.4M
$391M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
R&G PharmaStudies has a last 12-month revenue of $104M and a last 12-month EBITDA of $24.4M.
In the most recent fiscal year, R&G PharmaStudies achieved revenue of $103M and an EBITDA of $27.2M.
R&G PharmaStudies expects next 12-month revenue of XXX and NTM EBITDA of XXX
See R&G PharmaStudies valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $99.4M | $103M | XXX | XXX | XXX |
| Gross Profit | $32.4M | $39.5M | XXX | XXX | XXX |
| Gross Margin | 33% | 39% | XXX | XXX | XXX |
| EBITDA | $30.0M | $27.2M | XXX | XXX | XXX |
| EBITDA Margin | 30% | 27% | XXX | XXX | XXX |
| Net Profit | $15.7M | $22.4M | XXX | XXX | XXX |
| Net Margin | 16% | 22% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, R&G PharmaStudies's stock price is CNY 47 (or $6).
R&G PharmaStudies has current market cap of CNY 4.5B (or $622M), and EV of CNY 2.8B (or $391M).
See R&G PharmaStudies trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $391M | $622M | XXX | XXX | XXX | XXX | $0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, R&G PharmaStudies has market cap of $622M and EV of $391M.
R&G PharmaStudies's trades at 3.8x LTM EV/Revenue multiple, and 16.0x LTM EBITDA.
Analysts estimate R&G PharmaStudies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for R&G PharmaStudies and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $391M | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | 14.4x | XXX | XXX | XXX |
| P/E | 32.2x | XXX | XXX | XXX |
| P/E/Growth | 3.4x | XXX | XXX | XXX |
| EV/FCF | 21.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpR&G PharmaStudies's NTM/LTM revenue growth is 5%
R&G PharmaStudies's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, R&G PharmaStudies's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate R&G PharmaStudies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for R&G PharmaStudies and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -9% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 32% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 20% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
R&G PharmaStudies acquired XXX companies to date.
Last acquisition by R&G PharmaStudies was XXXXXXXX, XXXXX XXXXX XXXXXX . R&G PharmaStudies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was R&G PharmaStudies founded? | R&G PharmaStudies was founded in 2008. |
| Where is R&G PharmaStudies headquartered? | R&G PharmaStudies is headquartered in China. |
| Is R&G PharmaStudies publicy listed? | Yes, R&G PharmaStudies is a public company listed on SHE. |
| What is the stock symbol of R&G PharmaStudies? | R&G PharmaStudies trades under 301333 ticker. |
| When did R&G PharmaStudies go public? | R&G PharmaStudies went public in 2022. |
| Who are competitors of R&G PharmaStudies? | Similar companies to R&G PharmaStudies include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of R&G PharmaStudies? | R&G PharmaStudies's current market cap is $622M |
| What is the current revenue of R&G PharmaStudies? | R&G PharmaStudies's last 12-month revenue is $104M. |
| What is the current EBITDA of R&G PharmaStudies? | R&G PharmaStudies's last 12-month EBITDA is $24.4M. |
| What is the current EV/Revenue multiple of R&G PharmaStudies? | Current revenue multiple of R&G PharmaStudies is 3.8x. |
| What is the current EV/EBITDA multiple of R&G PharmaStudies? | Current EBITDA multiple of R&G PharmaStudies is 16.0x. |
| What is the current revenue growth of R&G PharmaStudies? | R&G PharmaStudies revenue growth between 2023 and 2024 was 3%. |
| Is R&G PharmaStudies profitable? | Yes, R&G PharmaStudies is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
